AK135

Phase 1Small molecule

AAkeso

AK135 is one of 34 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyNot yet recruiting

Peripheral NeuropathyPhase 1

Not yet recruiting

Competition

Competitive Landscape

39 competitors in Peripheral Neuropathy

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

9 2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

25 3

Savella

AbbVie

Approved

—4

Neurontin

VViatris Specialty LLC

Approved

3 5

Accupril

Pfizer

Approved

1 6

Velcade

SShilpa Grover, MD, MPH

Approved

1 7

Prilosec

DDexcel Pharma Technologies Ltd.

Adrucil

Cymbalta

2 10

Journavx

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Peripheral Neuropathy

NCT06860789

Clinical

Trials by Indication[1]

Peripheral Neuropathy1 trial

AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Not yet recruiting·AAkeso·Phase 1·NCT06860789·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AK135. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AK135 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AK135. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akeso company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAkeso

AK135

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News